AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Active Biotech

Declaration of Voting Results & Voting Rights Announcements May 31, 2018

3133_rns_2018-05-31_a8ec1a2c-e71f-4b65-a834-9094d0932d83.pdf

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

Number of shares and votes in Active Biotech

The number of shares and votes in Active Biotech has changed as a result of the recently completed rights issue.

Today, the last trading day of the month, there are in total 145,236,480 shares and votes in Active Biotech.

For further information, please contact: Hans Kolam, CFO Tel: +46 (0)46 19 20 44 E-mail: [email protected]

Active Biotech AB P.O. Box 724, SE-220 07 Lund, Sweden Phone +46 (0)46 19 20 00

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties is in development for neurodegenerative diseases in partnership with Teva Pharmaceutical Industries Ltd. ANYARA, an immunotherapy, in development for cancer indications in partnership with NeoTX Therapeutics Ltd. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit http://www.activebiotech.com/en for more information.

Active Biotech is required to publish the information contained in this press release in accordance with the Financial Instruments Trading Act. This information was provided to the media for publication at 08.30 am CET on May 31, 2018.

Talk to a Data Expert

Have a question? We'll get back to you promptly.